Why could vosaroxin improve responses to induction chemotherapy in patients with AML?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Stephen Strickland, Vanderbilt University, Nashville, US. We asked: Why could vosaroxin improve responses to induction chemotherapy in patients with acute myeloid leukemia?

Stephen Strickland explains that vasoroxin has the potential ability to improve upon the response rate of patients with AML, due to the fact is not a P-gp substrate and has p53 independent activity. He also explains that vasoroxin does not cause cardiac toxicity, which means more patients are eligible for its use.